Ebiomedicine

Journal Title：Ebiomedicine

The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell and The Lancet, to guide the launch of a new comprehensive, online-only open access Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences.

将生物医学研究的见解有效转化为改善人类健康是全球的首要任务。为此，爱思唯尔寻求其两大领先品牌《细胞》和《柳叶刀》的领导，指导推出一本新的综合性、在线开放获取的爱思唯尔期刊《EBioMedicine》，该期刊专注于形成一个跨越这一界面的社区，并为各自受众之间的对话和合作创造宝贵的机会。

Ebiomedicine创刊于2013年，由Elsevier BV出版商出版，收稿方向涵盖Biochemistry, Genetics and Molecular Biology - General Biochemistry,Genetics and Molecular Biology全领域，在行业领域中学术影响力很大，属于TOP期刊，国际一流期刊，关注度和专业度非常高，所以对原创文章要求创新性很高，过审难度很高，如果您有志于TOP期刊，建议关注此刊。平均审稿速度 5 Weeks ，影响因子指数9.7，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。